Schrodinger

SDGR · NASDAQ

$23.40+$0.28 (+1.21%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $23.12

SDGR analyst rating

BuyConsensus of 8 analysts over the last 12 months. 63% rate it a buy.

Strong buy0
Buy5
Hold3
Underperform0
Sell0

12-month price target · 9 analysts

Average $21.86 (−6.6% downside)

Low: $17.17
Now: $23.40
High: $31.50

Upgrades and downgrades

The latest rating actions, newest first

SDGR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Oct 20, 2026	Maintains	Neutral	$19.00 → $21.00	70%
Keybanc	Oct 16, 2026	Maintains	Overweight	$20.00 → $32.00	35%
TD Cowen	Oct 13, 2026	Maintains	Buy	$20.00 → $31.00	68%
BMO Capital	Oct 12, 2026	Maintains	Outperform	$24.00 → $30.00	57%
UBS	Aug 14, 2026	Initiates	Neutral	$13.00 → $19.00	70%
Morgan Stanley	May 14, 2026	Maintains	Equal-Weight	$19.00 → $17.00	48%
Keybanc	Apr 8, 2026	Maintains	Overweight	$25.00 → $20.00	44%
UBS	Mar 17, 2026	Maintains	Neutral	$18.00 → $13.00	53%
TD Cowen	Jan 8, 2026	Maintains	Buy	$33.00 → $24.00	68%
Keybanc	Jan 8, 2026	Maintains	Overweight	$28.00 → $25.00	35%

The case for and against

Updated Aug 28, 2024

Bull case

Schrodinger Inc. reported strong fourth-quarter software results, with software revenues exceeding consensus expectations by approximately 2% and reflecting a significant year-over-year growth of around 44%. The company's total annual contract value (ACV) rose by 9.7% to $154.2 million, while the retention rate for high-value customers remained robust at 98%, with an increase in the number of customers generating at least $1 million in ACV. Additionally, software gross margins expanded to an impressive 87%, indicating effective cost management and profitability within the software segment.

Bear case

Schrodinger Inc. has issued a lowered guidance for drug discovery revenue, projecting $30 million to $35 million for FY24, which marks a decline from the previous year's revenue of $45.4 million. The company reported a significant year-over-year decrease of 38.9% in drug discovery revenues for Q4 2023, coming in at $5.5 million, which was substantially below both internal expectations and consensus estimates. Furthermore, the company’s software revenue growth forecast for FY24 of 6-13% is below market expectations of 18%, combined with higher than anticipated R&D and G&A expenses, pointing to persistent financial pressures and a potentially challenging outlook ahead.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.